Comparison of posterior capsule opacification between the 1-piece and 3-piece Acrysof intraocular lenses: Two-year results of a randomized trial☆
Received 26 December 2003; accepted 5 March 2004. published online 16 September 2004.
Abstract
Purpose
To compare intensity of posterior capsule opacification (PCO) between the 1-piece and 3-piece haptic designs of an open-loop hydrophobic acrylic intraocular lens (IOL).
Design
A randomized, patient- and examiner-masked clinical trial with intraindividual comparison.
Participants
Fifty-two patients with bilateral age-related cataract (104 eyes).
Methods
Each patient had cataract surgery in both eyes and received a 1-piece Acrysof IOL in one eye and a 3-piece Acrysof IOL in the fellow eye. Follow-up examinations were at 1 week, 1 month, 6 months, 1 year, and 2 years. Patients were examined at the slit lamp, visual acuity (VA) was determined, and standardized high-resolution digital retroillumination images of the posterior capsule were taken. The intensity of PCO was assessed subjectively at the slit lamp and objectively using automated image analysis software.
There was no significant difference between IOL styles in best-corrected VA, rhexis/IOL overlap, capsular folds, and amount of anterior capsule opacification during the follow-up period. One year postoperatively, the amount of regeneratory PCO was higher for the 1-piece Acrysof eyes (image analysis software score: 1.3) than for the 3-piece Acrysof eyes (score: 0.9; P = 0.002). However, 2 years postoperatively, there was no significant difference between the 2 IOL styles (1-piece: 1.5; 3-piece: 1.3; P = 0.3). Neodymium:yttrium–aluminum–garnet capsulotomy was not performed in the study.
Conclusion
One year postoperatively, the 1-piece Acrysof showed slightly more regeneratory PCO than the 3-piece Acrysof. However, 2 years postoperatively, the barrier effect of the 1-piece design was comparable to that of the 3-piece haptic design, with low PCO intensity.
1Department of Ophthalmology, Medical University Vienna, Vienna, Austria
Correspondence and reprint requests to Oliver Findl, MD, Department of Ophthalmology, Medical University Vienna, Währinger Gürtel 18–20, 1090 Wien, Austria.
ABSTRACT